Effect of somatost atin, ulinastatin and gabexate on the trea tment of severe acute pancre atitis

American Journal of the Medical Sciences

Volumn 351, Issue 5, 2016, Pages 506-512

  Wang, Guiliang ^a,b   Liu, Yan ^b   Zhou, Shu Feng ^c   Qiu, Ping ^a   Xu, Linfang ^a   Wen, Ping ^a   Wen, Jianbo ^a   Xiao, Xianzhong ^d  

^a Department of Digestive Internal Medicine Gannan Medical University Pingxiang Hospital   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Central South University   (China)

Author keywords

Cytokine; Gabexate; Severe acute pancreatitis; Somatostatin; Ulinastatin

Indexed keywords

AMYLASE; GABEXATE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; SOMATOSTATIN; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; GLYCOPROTEIN; HORMONE; SERINE PROTEINASE INHIBITOR; TRYPSIN INHIBITOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; APACHE; ARTICLE; BREATHING RATE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RASH; TACHYCARDIA; THORAX DISEASE; TREATMENT OUTCOME; VOMITING; ACUTE DISEASE; COMBINATION DRUG THERAPY; MIDDLE AGED; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GABEXATE; GLYCOPROTEINS; HORMONES; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS; SOMATOSTATIN; TRYPSIN INHIBITORS;

EID: 84970974292     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2016.03.013     Document Type: Article

References (24)

1. Sabo A, Goussous N, Sardana N, et al. Necrotizing pancreatitis: a review of multidisciplinary management. J Pancreas 2015;16:125-35.
2. Zheng Y, Zhou Z, Li H, et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. Pancreas 2015;44:409-14.
3. Malmstrøm ML, Hansen MB, Andersen AM, et al. Cytokines and organ failure in acute pancreatitis: inflammatory response in acute pancreatitis. Pancreas 2012;41:271-7.
4. Kylänpää ML, Repo H, Puolakkainen PA. Inflammation and immuno-suppression in severe acute pancreatitis. World J Gastroenterol 2010;16: 2867-72.
5. da Costa DW, Boerma D, van Santvoort HC, et al. Staged multi-disciplinary step-up management for necrotizing pancreatitis. Br J Surg 2014;101:e65-79.
6. Feng C, Su X, Zhou X, et al. Early peritoneal lavage with ulinastatin improves outcome and enhances multi-organ protection in a model of severe acute pancreatitis. Exp Ther Med 2015;9:1171-7.
7. Ino Y, Arita Y, Akashi T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. World J Gastroenterol 2008;14:6382-7.
8. Büchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993;104:1165-70.
9. Bradley EL. 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992. Arch Surg 1993;128:586-90.
10. Kiriyama S, Gabata T, Takada T, et al. New diagnostic criteria of acute pancreatitis. J Hepatobiliary Pancreat Sci 2010;17(1):24-36.
11. Mayerle J, Dummer A, Sendler M, et al. Differential roles of inflammatory cells in pancreatitis. J Gastroenterol Hepatol 2012;27(suppl 2):47-51.
12. Phillip V, Steiner JM, Algül H. Early phase of acute pancreatitis: assessment and management. World J Gastrointest Pathophysiol 2014;5:158-68.
13. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet 2015;386 (9988):85-96.
14. Jiang CY, Wang W, Tang JX, et al. The adipocytokine resistin stimulates the production of proinflammatory cytokines TNF-α and IL-6 in pancreatic acinar cells via NF-κB activation. J Endocrinol Invest 2013; 36:986-92.
15. Surbatovic M, Radakovic S. Tumor necrosis factor-α levels early in severe acute pancreatitis: is there predictive value regarding severity and outcome? J Clin Gastroenterol 2013;47:637-43.
16. Park J, Chang JH, Park SH, et al. Interleukin-6 is associated with obesity, central fat distribution, and disease severity in patients with acute pancreatitis. Pancreatology 2015;15:59-63.
17. Fisic E, Poropat G, Bilic-Zulle L, et al. The role of IL-6, 8, and 10, sTNFr, CRP, and pancreatic elastase in the prediction of systemic complications in patients with acute pancreatitis. Gastroenterol Res Pract 2013;2013:282645.
18. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003;55:241-69.
19. Rotstein OD. Circulating cytokines in predicting development of severe acute pancreatitis. Crit Care 2014;18:575.
20. Li J, Wang R, Tang C. Somatostatin and octreotide on the treatment of acute pancreatitis-basic and clinical studies for three decades. Curr Pharm Des 2011;17:1594-601.
21. Andriulli A, Leandro G, Clemente R, et al. Meta-analysis of somatos-tatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998;12:237-45.
22. Chen S, Shi H, Zou X, et al. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor's New Clothes or Aladdin's Magic Lamp? Pancreas 2010;39: 1231-7.
23. Lee MF, Chang CW, Wang NM, et al. Serine protease inhibitor gabexate mesilate attenuates american cockroach-induced bronchial damage and inflammatory cytokine release. J Investig Allergol Clin Immunol 2014;24:338-45.
24. Yasunaga H, Horiguchi H, Hashimoto H, et al. Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database. Pancreas 2013;42:260-4.